188 related articles for article (PubMed ID: 38177459)
21. Precision medicine for advanced prostate cancer.
Mullane SA; Van Allen EM
Curr Opin Urol; 2016 May; 26(3):231-9. PubMed ID: 26909474
[TBL] [Abstract][Full Text] [Related]
22. Using circulating cell-free DNA to monitor personalized cancer therapy.
Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
[TBL] [Abstract][Full Text] [Related]
23. Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer.
Kwan EM; Wyatt AW
Prostate; 2022 Aug; 82 Suppl 1():S25-S36. PubMed ID: 35657159
[TBL] [Abstract][Full Text] [Related]
24. Clonality of localized and metastatic prostate cancer.
Boutros PC; Fraser M; van der Kwast T; Bristow RG
Curr Opin Urol; 2016 May; 26(3):219-24. PubMed ID: 26885716
[TBL] [Abstract][Full Text] [Related]
25. Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy.
VanderWeele DJ; Finney R; Katayama K; Gillard M; Paner G; Imoto S; Yamaguchi R; Wheeler D; Lack J; Cam M; Pontier A; Nguyen YTM; Maejima K; Sasaki-Oku A; Nakano K; Tanaka H; Vander Griend D; Kubo M; Ratain MJ; Miyano S; Nakagawa H
Eur Urol Focus; 2019 May; 5(3):416-424. PubMed ID: 29398457
[TBL] [Abstract][Full Text] [Related]
26. An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer.
Dawson NA; Zibelman M; Lindsay T; Feldman RA; Saul M; Gatalica Z; Korn WM; Heath EI
Mol Cancer Ther; 2020 Jun; 19(6):1373-1382. PubMed ID: 32220973
[TBL] [Abstract][Full Text] [Related]
27. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
[TBL] [Abstract][Full Text] [Related]
28. Multiregion whole-exome sequencing of matched primary and metastatic tumors revealed genomic heterogeneity and suggested polyclonal seeding in colorectal cancer metastasis.
Wei Q; Ye Z; Zhong X; Li L; Wang C; Myers RE; Palazzo JP; Fortuna D; Yan A; Waldman SA; Chen X; Posey JA; Basu-Mallick A; Jiang BH; Hou L; Shu J; Sun Y; Xing J; Li B; Yang H
Ann Oncol; 2017 Sep; 28(9):2135-2141. PubMed ID: 28911083
[TBL] [Abstract][Full Text] [Related]
29. Re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020;78:652-6: Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?
Kaochar S; Mitsiades N
Eur Urol; 2021 Mar; 79(3):e91-e93. PubMed ID: 33358624
[No Abstract] [Full Text] [Related]
30. Prostate epithelial genes define therapy-relevant prostate cancer molecular subtype.
Han H; Lee HH; Choi K; Moon YJ; Heo JE; Ham WS; Jang WS; Rha KH; Cho NH; Giancotti FG; Choi YD
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1080-1092. PubMed ID: 33903734
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration-Sensitive Prostate Cancer.
Wei Y; Wu J; Gu W; Wang J; Lin G; Qin X; Dai B; Gan H; Ye D; Zhu Y
Oncologist; 2020 Jul; 25(7):e1042-e1050. PubMed ID: 32190957
[TBL] [Abstract][Full Text] [Related]
32. Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma.
Chedgy EC; Vandekerkhove G; Herberts C; Annala M; Donoghue AJ; Sigouros M; Ritch E; Struss W; Konomura S; Liew J; Parimi S; Vergidis J; Hurtado-Coll A; Sboner A; Fazli L; Beltran H; Chi KN; Wyatt AW
J Pathol; 2018 Oct; 246(2):244-253. PubMed ID: 30015382
[TBL] [Abstract][Full Text] [Related]
33. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
Beltran H; Yelensky R; Frampton GM; Park K; Downing SR; MacDonald TY; Jarosz M; Lipson D; Tagawa ST; Nanus DM; Stephens PJ; Mosquera JM; Cronin MT; Rubin MA
Eur Urol; 2013 May; 63(5):920-6. PubMed ID: 22981675
[TBL] [Abstract][Full Text] [Related]
34. Heterogeneity in Genomic Risk Assessment from Tissue Based Prognostic Signatures Used in the Biopsy Setting and the Impact of Magnetic Resonance Imaging Targeted Biopsy.
Punnen S; Stoyanova R; Kwon D; Reis IM; Soodana-Prakash N; Ritch CR; Nahar B; Gonzalgo ML; Kava B; Liu Y; Arora H; Gaston SM; Castillo Acosta RP; Pra AD; Abramowitz M; Kryvenko ON; Davicioni E; Pollack A; Parekh DJ
J Urol; 2021 May; 205(5):1344-1351. PubMed ID: 33356482
[TBL] [Abstract][Full Text] [Related]
35. Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancer.
Antonarakis ES; Tierno M; Fisher V; Tukachinsky H; Alexander S; Hamdani O; Hiemenz MC; Huang RSP; Oxnard GR; Graf RP
Prostate; 2022 May; 82(7):867-875. PubMed ID: 35286728
[TBL] [Abstract][Full Text] [Related]
36. Transcriptomic heterogeneity in multifocal prostate cancer.
Salami SS; Hovelson DH; Kaplan JB; Mathieu R; Udager AM; Curci NE; Lee M; Plouffe KR; de la Vega LL; Susani M; Rioux-Leclercq N; Spratt DE; Morgan TM; Davenport MS; Chinnaiyan AM; Cyrta J; Rubin MA; Shariat SF; Tomlins SA; Palapattu GS
JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385730
[TBL] [Abstract][Full Text] [Related]
37. Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer.
Zhu J; Tucker M; Marin D; Gupta RT; Healy P; Humeniuk M; Jarvis C; Zhang T; McNamara M; George DJ; Wu Y; Lisi S; Armstrong AJ
Urol Oncol; 2019 Nov; 37(11):813.e1-813.e9. PubMed ID: 31327751
[TBL] [Abstract][Full Text] [Related]
38. Germline and somatic DNA repair gene alterations in prostate cancer.
Dall'Era MA; McPherson JD; Gao AC; DeVere White RW; Gregg JP; Lara PN
Cancer; 2020 Jul; 126(13):2980-2985. PubMed ID: 32315455
[TBL] [Abstract][Full Text] [Related]
39. Technical and biological constraints on ctDNA-based genotyping.
Herberts C; Wyatt AW
Trends Cancer; 2021 Nov; 7(11):995-1009. PubMed ID: 34219051
[TBL] [Abstract][Full Text] [Related]
40. Genomic heterogeneity as a barrier to precision oncology in urothelial cancer.
Clinton TN; Chen Z; Wise H; Lenis AT; Chavan S; Donoghue MTA; Almassi N; Chu CE; Dason S; Rao P; Rodrigues JA; Vasani NB; Ridouani F; Rosenberg JE; Bajorin DF; Teo MY; Bochner BH; Berger MF; Ostrovnaya I; Pietzak EJ; Iyer G; Gao SP; Hu W; Al-Ahmadie HA; Solit DB
Cell Rep; 2022 Dec; 41(12):111859. PubMed ID: 36543146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
